Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …

Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Background The KRAS oncogene is a driver mutation and is present in greater than 90% of
pancreatic ductal adenocarcinomas (PDAC). A subset of these tumors, however, do not …

The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …

Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …

Abstract Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC)
do not harbor mutations in KRAS. Understanding the unique molecular and clinical features …

Background KRAS variant alleles may have differential biological properties which impact
prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). Materials …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors, with a 5-
year survival rate of less than 10%. At present, the comprehensive treatment based on …

Pancreatic ductal adenocarcinoma (PDAC) is almost universally fatal. The annual number of
deaths equals the number of newly diagnosed cases, despite maximal treatment. The …